AOD-9604 in Westhaven-Moonstone — Fat Loss Peptide Research Guide
AOD-9604 research guide for Westhaven-Moonstone. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
Research-Grade AOD-9604 for Westhaven-Moonstone Investigators
AOD-9604 isn't stocked on pharmacy shelves in Westhaven-Moonstone or anywhere else for that matter — it's a research compound available through a dedicated online market. What this means for Westhaven-Moonstone researchers is that your location matters far less than your ability to assess COA data — and those quality checks are available to every researcher. What consistently distinguishes top AOD-9604 vendors is full COA coverage: HPLC for purity, mass spec for identity and weight verification, and endotoxin testing for contamination assurance. This guide guides Westhaven-Moonstone researchers through that evaluation process and explains the signals that distinguish quality AOD-9604 suppliers.
What Studies Say About AOD-9604
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Westhaven-Moonstone studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
How to Source AOD-9604 — Vendor Guide
Vetting AOD-9604 vendors starts with the COA: locate the batch-specific certificate before placing an order, not after. When reviewing a AOD-9604 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are at acceptable levels for the intended application. Red flags in AOD-9604 vendor evaluation: prices far under typical market pricing, vague sourcing information, no community presence, and COAs that lack endotoxin data. The lyophilised (freeze-dried) form of AOD-9604 is far superior to liquid pre-made solutions — lyophilised powder stays viable for years at −20°C, while liquid preparations degrade within weeks even when refrigerated.
Order AOD-9604 — ships to Westhaven-Moonstone
COA-verified · International tracking · Research grade
As a research compound, AOD-9604 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and restricted human research data. Reconstitute AOD-9604 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — providing 25mcg per unit measured on a 100-unit syringe. Endotoxin testing in the AOD-9604 COA is not optional — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at trace quantities, and no pricing advantage justifies skipping this verification. Protocol documentation — recording exactly what was used, when, and how — is a sound practice for any AOD-9604 protocol that ensures unusual findings can be explained.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
